Leo Holmgren

Leo Holmgren is the CEO of TIRmed Pharma, a pharmaceutical company focused on developing innovative treatments for inflammatory skin disorders, particularly Atopic Dermatitis.13

Professional Background

Leo Holmgren has a strong background in business strategy and pharmaceuticals:

• He is a former consultant at Boston Consulting Group (BCG)4
• During his time at BCG, he gained experience advising on pharmaceutical deals and large strategic projects34
• He holds a master's degree from London Business School24

Role at TIRmed Pharma

As CEO, Holmgren leads TIRmed Pharma in its mission to develop a new generation of treatments for inflammatory skin disorders. The company's key product is an oligonucleotide-based treatment that shows promise in providing long-lasting symptom relief for conditions like Atopic Dermatitis.1

Company Vision

Under Holmgren's leadership, TIRmed Pharma is working on a unique approach to skin disorder treatment:

• Their product aims to provide symptom relief with only 10 applications per year, as opposed to daily treatments typical of many topical medications1
• The company is focused on aligning its strategy with FDA requirements and building a network in the United States to support their goals1

Networking and Growth

Holmgren has been actively involved in expanding TIRmed Pharma's presence and connections:

• He participated in the SIREUS Entrepreneurs Forum and Destination Startup® events to increase the company's visibility and networking opportunities1
• These events have helped TIRmed Pharma prepare for future fundraising activities and potential expansion into the U.S. market1

Leo Holmgren's LinkedIn username is leo-holmgren, as confirmed by the query and search results.2